Mechanism of Botulinum A & Clinical Applications

Caroline Cho

doi:10.58445/rars.1781

##article.authors##

Caroline Cho Arnold O. Beckman High School

DOI:

https://doi.org/10.58445/rars.1781

Keywords:

botox, migraines

Abstract

This project investigates botulinum toxin's molecular mechanisms and clinical applications through Botox injections, focusing on its effects at neuromuscular junctions, acetylcholine release inhibition, and muscle contraction impacts. It examines neurological effects, both therapeutic and adverse, with emphasis on migraine treatment efficacy and potential risks. The study explores Botox's action in blocking pain-causing neuropeptides for migraine relief and its use in treating hyperhidrosis by inhibiting sweat gland acetylcholine release. The research aims to enhance understanding of Botox's physiological impacts, improve patient selection, and increase treatment safety across various clinical applications.

References

Fortune Business Insights. (2022). Botox Market Size, Share & COVID-19 Impact Analysis, By Application (Therapeutics and Aesthetic), By End-user (Medical Spas and Beauty Centers, Hospitals, and Dermatology Clinics), and Regional Forecast, 2021-2028. Retrieved from https://www.fortunebusinessinsights.com/industry-reports/botox-market-100996

Nigam, P. K., & Nigam, A. (2010). Botulinum toxin. Indian Journal of Dermatology, 55(1), 8-14. https://doi.org/10.4103/0019-5154.60343

Brunger, A. T., Cipriano, D. J., & Diao, J. (2015). Towards reconstitution of membrane fusion mediated by SNAREs and other synaptic proteins. Critical Reviews in Biochemistry and Molecular Biology, 50(3), 231-241. https://doi.org/10.3109/10409238.2015.1028594

Pellizzari, R., Rossetto, O., Schiavo, G., & Montecucco, C. (1999). Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 354(1381), 259-268. https://doi.org/10.1098/rstb.1999.0374

Gul, N., Smith, L. A., & Ahmed, S. A. (2010). Light chain separated from the rest of the type A botulinum neurotoxin molecule is the most catalytically active form. PLoS One, 5(9), e12872. https://doi.org/10.1371/journal.pone.0012872

Anandan, C., & Jankovic, J. (2021). Botulinum toxin in movement disorders: An update. Toxins, 13(1), 42. https://doi.org/10.3390/toxins13010042

Albanese, A., Abbruzzese, G., Dressler, D., Duzynski, W., Khatkova, S., Marti, M. J., ... & Tzoulis, C. (2015). Practical guidance for CD management involving treatment of botulinum toxin: A consensus statement. Journal of Neurology, 262(9), 2201-2213. https://doi.org/10.1007/s00415-015-7846-8

Silberstein, S. D., Blumenfeld, A. M., Cady, R. K., Turner, I. M., Lipton, R. B., Diener, H. C., ... & Dodick, D. W. (2013). OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Journal of the Neurological Sciences, 331(1-2), 48-56. https://doi.org/10.1016/j.jns.2013.05.010

Koptielow, J., Szyłak, E., Szewczyk-Roszczenko, O., Roszczenko, P., Kochanowicz, J., Kułakowska, A., & Chorąży, M. (2024). Genetic update and treatment for dystonia. International Journal of Molecular Sciences, 25(7), 3571. https://doi.org/10.3390/ijms25073571

Albanese, A., Bhatia, K. P., Cardoso, F., Comella, C., Defazio, G., Fung, V. S., ... & Vidailhet, M. (2023). Isolated cervical dystonia: Diagnosis and classification. Movement Disorders, 38(8), 1367-1378. https://doi.org/10.1002/mds.29254

Castelao, M., Marques, R. E., Duarte, G. S., Rodrigues, F. B., Ferreira, J., Sampaio, C., ... & Costa, J. (2017). Botulinum toxin type A therapy for cervical dystonia. The Cochrane Database of Systematic Reviews, 2017(12). https://doi.org/10.1002/14651858.CD003633.pub5

Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B., ... & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 30(7), 793-803. https://doi.org/10.1177/0333102410364676

Dressler, D., Adib Saberi, F., & Rosales, R. L. (2021). Botulinum toxin therapy of dystonia. Journal of Neural Transmission, 128(4), 531-537. https://doi.org/10.1007/s00702-020-02281-9

Lacković, Z. (2021). Botulinum toxin and pain. In F. Rosales, J. Jankovic, & D. Dressler (Eds.), Botulinum Toxin Therapy (pp. 251-264). Springer. https://doi.org/10.1007/978-3-030-70965-2_16

Bakheit, A. M. O., Pittock, S., Moore, A. P., Wurker, M., Otto, S., Erbguth, F., & Coxon, L. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. European Journal of Neurology, 8(6), 559-565. https://doi.org/10.1046/j.1468-1331.2001.00271.x

Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., ... & Zochodne, D. (2011). Evidence-based guideline: Treatment of painful diabetic neuropathy. PM&R, 3(4), 345-352. https://doi.org/10.1016/j.pmrj.2010.12.022

Carruthers, J. A., Lowe, N. J., Menter, M. A., Gibson, J., Nordquist, M., Mordaunt, J., ... & Group, B. G. L. I. S. (2002). A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology, 46(6), 840-849. https://doi.org/10.1067/mjd.2002.120202

Charles, A. (2009). Advances in the basic and clinical science of migraine. Annals of Neurology, 65(5), 491-498. https://doi.org/10.1002/ana.21690

Grenda, T., Grenda, A., Krawczyk, P., & Kwiatek, K. (2022). Botulinum toxin in cancer therapy—Current perspectives and limitations. Applied Microbiology and Biotechnology, 106(2), 485-495. https://doi.org/10.1007/s00253-022-11739-7

Albanese, A., et al. (2015). Practical guidance for CD management involving treatment of botulinum toxin: A consensus statement. Journal of Neurology. https://doi.org/10.1007/s00415-015-7846-8

Silberstein, S. D., et al. (2013). OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Journal of the Neurological Sciences. https://doi.org/10.1016/j.jns.2013.05.010

Jankovic J., et al. (2017). Study on Botox injections providing symptom relief for cervical dystonia. Movement Disorders Journal. https://doi.org/10.1002/mds.27095

Movement Disorders. (2017). Botox in cervical dystonia study. Movement Disorders Journal. https://doi.org/10.1002/mds.27095

Large-scale survey of 616 patients with cervical dystonia treated with Botox. (2017). Movement Disorders Journal. https://doi.org/10.1002/mds.27095

Silberstein et al. (2013). Chronic migraine treatment PREEMPT trial. Journal of the Neurological Sciences. https://doi.org/10.1016/j.jns.2013.05.010

Large-scale study on Botox for chronic migraine. (2013). Journal of the Neurological Sciences. https://doi.org/10.1016/j.jns.2013.05.010

Naumann, M., & Jankovic, J. (2004). Safety of botulinum toxin type A: A systematic review and meta-analysis. Movement Disorders, 19(10), 1337-1348. https://doi.org/10.1002/mds.20207

U.S. Food and Drug Administration (FDA). (2009). FDA approves Boxed Warning for botulinum toxin products. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-boxed-warning-botulinum-toxin-products

U.S. Food and Drug Administration (FDA). (2009). FDA issues boxed warning for Botox. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-boxed-warning-botulinum-toxin-products

Clinical research on optimizing Botox injection techniques. (2021). Journal of Neurology. https://doi.org/10.1007/s00415-015-7846-8

Combining Botox with other treatments. (2021). Journal of Neurology. https://doi.org/10.1007/s00415-015-7846-8

Duration of Botox effects lasting 3-4 months. (2021). Journal of Neurology. https://doi.org/10.1007/s00415-015-7846-8

Bril, V., et al. (2011). Painful diabetic neuropathy treatment study. PM&R, 3(4), 345-352. https://doi.org/10.1016/j.pmrj.2010.12.022

Preliminary studies on ACh inhibition and tumor growth. (2022). Applied Microbiology and Biotechnology, 106(2), 485-495. https://doi.org/10.1007/s00253-022-11739-7

Naumann, M., & Jankovic, J. (2004). Adverse effects in botulinum toxin treatments. Movement Disorders, 19(10), 1337-1348. https://doi.org/10.1002/mds.20207

Mechanism of Botulinum A & Clinical Applications

##article.authors##

DOI:

Keywords:

Abstract

References

Downloads

Posted

Categories

License